Kornimate/medical-research-clean huggingface dataset:
effects of nature exposure intervention on soccer performance among mentally fatigued university players

Conditions: Mental Fatigue

Summary: the current study is going to investigate the nature exposure intervention on the ability of self-regulation and decision-making skills among mentally fatigued soccer players. the subjects will be instructed to view some nature photos, which can facilitate the recovering process for directed attention and the ability of self-regulation. thus, to see the improvement in decision-making skills.

the intervention of this study is nature exposure, specifically, instruct subjects to view and immerse in some nature photos due to the humanity of biophilia. the condition of mental fatigue will be induced by the stroop task. before the intervention or process of viewing photos, the baseline will be recorded to compare the post-test value of self-regulation and the score of decision-making skills. moreover, the different durations of viewing photos will be implemented to identify the optimal selection.

Eligibility criteria:
inclusion criteria: * the selection of the participants will be every position without the goalkeeper. the age of them will be at 18-24 years. only male players will be selected. players should have at least played from the senior school and have 3 years' training experience. exclusion criteria: * the study will exclude color blindness, for the stroop task will involve color. self-reports should be free of any known disease or sleep disorder and not currently taking any medication.

Keywords: decision-making skills self-regulation mental fatigue soccer performance
clinical study of hepatocyte transplantation for liver cirrhosis

Conditions: Liver Cirrhosis

Summary: the primary objective: to observe and determine the safety and tolerance of allogeneic hepatocyte transplantation in patients with liver cirrhosis and to establish the maximum-tolerated dose (mtd) and evaluate the dose-limiting toxicities (dlts). the secondary objective: to observe the therapeutic efficacy of allogeneic hepatocyte transplantation for liver cirrhosis.

* a traditional 3 + 3 dose escalation design will be implemented. * successive cohorts of participants (3 or 3+3 participants /cohort) will start on a fixed cell numbers of allogeneic hepatocyte in three cohorts separately: l dose (low cell numbers); m dose (medium cell numbers); h dose (high cell numbers). * the 1st cohort will be given dose of l. * the 2nd cohort will be given dose of m. * the 3rd cohort will be given dose of h. * dose escalation will continue until the maximum-tolerated dose (mtd). if no dlts are observed for 28days after administration of the last dose, a new cohort will be enrolled at the next planned dose level. if dlts are observed in 2 of the three participants, the mtd will be determined to be the dose administered to the previous cohort. if dlts are observed in one participant in the cohort, another three participants will be treated with the same dose level. if the new three participants aren't observed dlts, another cohort will be enrolled at the upper dose. if at least one of the new three ones are observed dlts, the below dose will be the mtd. * mtd will stopped by testing increasing up to the h dose. * toxicities will be graded using the common terminology criteria for adverse events version 5.0 (ctcae 5.0).

Eligibility criteria:
key inclusion criteria: * the age at the time of signing the informed consent from 18 to 70 years old (including the boundary value), both male and female; * clinical diagnosis of liver cirrhosis; * be able to understand and sign informed consent. key exclusion criteria: * combined with liver cancer or other malignant tumors; * patients who can't cooperate; * prothrombin time (pt) exceeded the upper limit of normal control for 3-5 seconds or more; * international normalized ratio (inr) \>1.5; * plt\<60×109/l； * recently use of anticoagulant or antiplatelet drugs (last 7 days); * recently (last 4 weeks) had upper gastrointestinal bleeding or spontaneous celiac inflammation; * moderate or large amount of ascites; * the investigator assesses that the patient is unable or unwilling to comply with the protocol.

Keywords: liver cirrhosis; allogeneic hepatocyte; transplantation
pet study to determine the relationship between plasma concentrations and muscarinic type 1 receptor (m1achr) occupancy of pipe-307 in healthy volunteers

Conditions: Multiple Sclerosis

Summary: this is a phase 1, single-center, open-label, adaptive-design pet study to investigate the occupancy of brain muscarinic type 1 receptors (m1achr) by pipe-307 in healthy volunteers.

this is a phase 1, single-center, open-label, adaptive-design study to investigate the occupancy of brain m1achr after a single oral dose of pipe-307 in healthy volunteers by positron emission tomography (pet) using the radioligand \[11c\] pipe-307. this study will have an adaptive design to adequately evaluate the relationship between pipe-307 exposure and brain m1achr occupancy.

Eligibility criteria:
key criteria: * normotensive male or female volunteers between 25-65 years old * deemed healthy on the basis of a clinical history, physical examination, ecg, vital signs, and laboratory tests of blood and urine key exclusion criteria: * clinically relevant abnormal findings at the screening assessments * clinically relevant abnormal medical history or concurrent medical condition * acute or chronic illness * contraindications to mri, ct, pet, or arterial cannulation procedures * significant exposure to research related radiation or other exposure (defined as icrp category iib or no more than 10 msv) * positive tests for hepatitis b surface antigen (hbsag) \& hepatitis c virus (hcv) antibody, human immunodeficiency virus (hiv) antibody * drug or alcohol abuse * smoke more than 10 cigarettes daily * loss of more than 400 ml blood * vital signs or ecgs outside the acceptable range

Keywords: multiple sclerosis
evaluation of efficacy and safety of epidural steroid injection using dexamethasone or betamethasone

Conditions: Back Pain; Neck Pain

Summary: particle steroid drug such as triamcinolone has been used widely for epidural steroid injection (esi) treatment in korea. however, korea fda recently prohibit esi using triamcinolone, following the regulation of us fda. therefore, dexamethasone and betamethasone become only candidate drugs for esi in korea and the investigators are curious about the effectiveness and safety of both drugs due to limitation of information about comparison of two drugs in previous literature. so, this study aims to compare the effectiveness and safety of both drugs and our hypothesis is that there is no difference of the effectiveness between dexamethasone and betamethasone at 2 weeks after esi.


Eligibility criteria:
inclusion criteria: 1. patients with spinal pain (i.e.neck pain, back pain, or radiculopathy..) 2. patients with informed consent 3. visual analog scale (vas) is five or more in 10-point scale at screening 4. sustained spinal pain, regardless of sufficient conservative treatment (i.e. oral medicine, physical therapy..) exclusion criteria: 1. age of patient less than 19 years 2. relative contraindication of epidural steroid injection, as follows: * pregnant or breast-feeding state * uncontrolled coagulopathy * suspected of active infection state * uncontrolled diabetes mellitus * previous history of adverse event related to epidural steroid injection

Keywords: dexamethasone betamethasone epidural steroid injection comparative effectiveness research
evaluation of the tecnis™ multifocal and crystalens™ accommodating intraocular lenses

Conditions: Aphakia

Summary: the purpose of this study is to compare the visual outcomes with bilateral implantation of tecnis mf and crystalens™ ao aberration-free accommodating intraocular lens (iols) 6 months after post cataract surgery.


Eligibility criteria:
inclusion criteria: * age 18 or greater * bilateral cataracts for which phacoemulsification extraction and posterior iol implantation has been planned for both eyes * visual potential of 20/25 or better in each eye after cataract removal and iol implantation * preoperative best-corrected distance visual acuity (bcdva) worse than 20/40 snellen * naturally dilated pupil size (in dim light) \> 4.0 mm (with no dilation medications) for both eyes * preoperative corneal astigmatism of 1.0 d or less * clear intraocular media other than cataract * availability, willingness, and sufficient cognitive awareness to comply with examination procedures exclusion criteria: * use of systemic or ocular medications that may affect vision * acute or chronic disease or illness that would increase risk or confound study results (e.g. diabetes mellitus, immunocompromised, etc.) * subjects with diabetes mellitus * uncontrolled systemic or ocular disease * history of ocular trauma or prior ocular surgery * amblyopia or strabismus * known pathology that may affect visual acuity; particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) * diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal disorders) that are predicted to cause future acuity losses to a level of 20/30 or worse * subjects who may be expected to require retinal laser treatment or other surgical intervention * capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome) * pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 4.0 mm under mesopic/scotopic conditions) * contact lens usage within 6 months for pmma contacts lenses, 1 month for gas permeable lenses or 1 week for extended-wear and daily-wear soft contact lenses * requiring an intraocular lens \ 26.0 diopters

Keywords: aphakia following refractive lensectomy to treat presbyopia
clic1 in patients presenting pd

Conditions: Hip Fractures; Hip Disease

Summary: in this study, mononuclear cells, particularly monocytes, were collected from the peripheral blood of elderly patients who underwent orthopedic hip surgery under spinal anesthesia. we then observe the accumulation of chloride intracellular channel 1 (clic1), particularly the characteristic accumulation morphology and its function. the purpose of this study is to compare whether there is a difference in the degree and form of cytoplasmic clic1 accumulation between the elderly group with postoperative delirium (pd) and the elderly group without postoperative delirium. we'll also confirm whether this is appropriate as a predictor of postoperative delirium. in addition, we will establish a control group for the non-elderly group to check the difference due to aging itself.


Eligibility criteria:
inclusion criteria: male or female patients aged 65 years or older who are scheduled to undergo surgery for an orthopedic hip fracture under spinal anesthesia exclusion criteria: * patients who are unconscious * patients who are unable to communicate * alzheimer * parkinson disease * conversion to general anesthesia
neuroinflammation, serotonin, impulsivity and suicide

Conditions: Major Depressive Episode; Suicidal Behavior

Summary: suicide is a major health problem that causes annually a million death worlwide. in the stress-vulnerability model, suicidal behavior (sb) results from the interaction between an individual's predisposition (personality, family history of sb...) and stressful conditions (early life adversity). studies show that suicide ideations could favour inflammation and that depression is associated with an elevated inflammation. recent evidences also suggest that inflammatory mediators play a critical role in sb. the aim of the study is to evaluate the inflammatory markers rate on depressed patients with or without personal history of sb. in the second part of the study, the relations between the rates of inflammatory markers and characteristics of sb, impulsivity, psychological pain, childhood abuse and gene expression of 5ht2b receptor will be investigated.

over one year, we will recruit 280 patients suffering from a major depressive episode with (n=140) and without any history of suicide attempt (n=140), from a specialized clinic for mood disorders and sb. first visit : clinical, biological and neuropsychological assessment second visit, at 6 month : follow-up visit in the department or interview by telephone in order to assess suicidal ideations or suicide attempts since the inclusion.

Eligibility criteria:
inclusion criteria: * ages of 18 and 65 * main diagnosis of major depressive episode (dsm-iv criteria) * having signed the informed consent * able to understand nature, aims, and methodology of the study specifics inclusion criteria: * depressed patients with suicide attempt history : * have done in his lifetime at least one suicide attempt (however the period of time between inclusion and suicide attempt) * depressed patients without suicide attempt history : * had never realized suicide attempt in his lifetime exclusion criteria: * patients suffering from inflammatories pathology * antibiotic or anti-inflammatory current treatment * pregnancy * participation in another clinical trial with an exclusion period * patient on protective measures (guardianship or trusteeship)

Keywords: psychiatry depressive disorder suicide inflammation
contrast-enhanced us of spleen, liver and kidney

Conditions: Malaria; Pyelonephritis; Bacterial Infections

Summary: to evaluate the changes in the microcirculation of the liver, kidney and spleen during acute infection in patients with malaria (cohorts 1 and 3) and other infectious diseases such as acute pyelonephritis at day 0 (within 8 hours of the treatment start), day 2 to 4 and day 28-32, using functional us with continuous infusion of a contrast agent (sonovue, bracco, italy). study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the su signals is performed with destruction reperfusion kinetics.

to evaluate the changes in the microcirculation of the liver, kidney and spleen during acute infection in patients with malaria (cohorts 1 and 3) and other infectious diseases such as acute pyelonephritis at day 0 (within 8 hours of the treatment start), day 2 to 4 and day 28-32, using functional us with continuous infusion of a contrast agent (sonovue, bracco, italy). three cohortes will be studied: cohorte 1 infection at plasmodium falciparum (24 patients), cohorte 3 infection at plasmodium vivax, ovale or malariae (5 patients) and cohorte 2 other infectious diseases such as acute pyelonephritis (24 patients). study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the su signals is performed with destruction reperfusion kinetics.

Eligibility criteria:
inclusion criteria: * social security number * age over 18 * acute malaria infection or other infectious diseases * inpatients * signed informed consent form exclusion criteria: * pregnancy * criteria of bad tolerance of infection * treatment started for more than 8 hours * lack of cooperation * history of splenectomy, hematological disease, cirrhosis with portal hypertension, splenomegaly * medical treatment with beta blocker, diuretic, immunodepression drugs

Keywords: functional study contrast-enhanced us perfusion
persistence of the immune response to hepatitis b in 4-6 years old children previously vaccinated with dtpa-hbv-ipv/hib

Conditions: Hepatitis B

Summary: persistence of seroprotective antibody concentrations \& immunological memory shown by the ability to mount a response to a challenge dose of hbv vaccine


Eligibility criteria:
inclusion criteria: * a male or female aged 4 to 6 years at the time of study entry . * subjects who have received a total of 4 doses of dtpa-hbv-ipv/hib vaccine in previous vaccination studies. * evidence of previous hepatitis b booster vaccination or disease since administration of the fourth dose of dtpa-hbv-ipv/hib vaccine.

Keywords: prophylaxis for hepatitis b disease
a clinical study of tqb2029 for injection in subjects with multiple myeloma

Conditions: Multiple Myeloma

Summary: this is a study to evaluate the maximum tolerated dose (mtd), dose limiting toxicity (dlt), occurrence of all adverse events (aes) and serious adverse events (saes), pharmacokinetic parameters, pharmacodynamic parameters, immunogenicity, and anti-tumor effects of tqb2029 for injection in chinese adult subjects with multiple myeloma. the study is divided into phase ia and ib, phase ia: dose escalation phase, to evaluate the safety and tolerability of tqb2029 for injection, and determining dlt and mtd; phase ib: dose extension phase, to evaluate the effectiveness of tqb2029 for injection in subjects with multiple myeloma.


Eligibility criteria:
inclusion criteria: * subjects who voluntarily join the study, sign the informed consent form, and have good compliance. * aged from 18 to 75 years; eastern cooperative oncology group performance status score: 0-2; at least 12 weeks expected survival period. * multiple myeloma with diagnostic records and meeting the international myeloma working group (imwg) diagnostic criteria * there are measurable lesions present * the function of main organs is normal. * subjects need to adopt effective methods of contraception. exclusion criteria: * subjects who have taken chinese patent medicines with anti-tumor indications in the drug instructions that national medical products administration approved within 2 weeks before the first administration. * subjects who received targeted therapy or immunotherapy within 3 weeks before the first medication * subjects who is known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent. * subjects who has had or currently has other malignant tumors within the past 3 years prior to the first use of medication * subjects who with unrelieved toxic reactions above common terminology criteria for adverse events (ctc ae) grade 1 caused by any previous treatment * subjects who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication * subjects who have experienced arterial/venous thrombotic event occurred within 6 months prior to the first administration * subjects with a history of psychotropic drug abuse unable to quit or with mental disorders; * subjects with any severe and/or uncontrolled disease * according to the judgment of the investigators, there are accompanying diseases that seriously endanger the safety of patients or affect the completion of the study.
post operative dressing after clean elective hand surgery

Conditions: Trigger Finger Disorder; Carpal Tunnel Syndrome; Ganglion

Summary: very little has been published about the optimal post operative dressing protocol, and no practical conclusion has emerged from a meta-analysis published in 2013. even fewer studies focused on that topic specifically in hand surgery. nevertheless, the functional impairment due to a dressing in the hand is much greater than anywhere else, due to the constant use of hands in daily life activities. yet, habits differs widely following surgeon's preference, from daily change with application of an antimicrobial unguent, to unchanged dressing until the first follow up consultation after 2 weeks, to complete removal of the dressing and basic soap and water cleaning at postoperative day (pod) 1. those varying recommendations have functional and logistical implication for the patients, especially the elderlies, for whom autonomy is a fragile status that can be dramatically impaired by such protocols. the goal of this study is to define which post operative dressing protocol is optimal in terms of wound complications (disunion, infection)


Eligibility criteria:
inclusion criteria: \* elective hand surgery with clean wound (type 1 in wound classification of american college of surgeon 11) - (carpal tunnel, trigger finger, cyst removal or foreign body removal, tendon release). exclusion criteria: * insertion of hardware * known skin condition disturbing normal healing, * immunodeficiency, * incapacity to understand or to observe the self cleaning protocol. * unexpected peroperative complication leading to a modification of the operative technique.
genomic predictors of papillary microcarcinoma disease progression

Conditions: Papillary Microcarcinoma

Summary: the study is being done to answer the following question: what are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic? therefore, the purpose of this study is to identify specific clinical and molecular characteristics that are predictive of tumor progression in small thyroid cancers.


Eligibility criteria:
inclusion criteria: * biopsy proven papillary thyroid cancer (or suspicious for papillary thyroid cancer) confirmed by mskcc cytopathologist. * being followed with active surveillance at mskcc * biopsied index nodule less than or equal to 2 cm in maximum dimension * thyroid and neck us performed and interpreted by a mskcc radiologist within 6 months prior to study entry. exclusion criteria: * biopsied index nodule greater than 2 cm in any dimension * age less than 18 yrs old

Keywords: genomic predictors 14-277
study of antidepressant efficacy of a selective, high affinity enkephalinergic agonist in anxious major depressive disorder (amdd)

Conditions: Anxious Major Depressive Disorder

Summary: this study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.


Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures * diagnosis of major depressive disorder without psychotic features (mdd) exclusion criteria: * a history of substance or alcohol abuse within the past 6 months or dependence within 1 year of enrollment as defined by dsm-iv criteria. * women that are pregnant or lactating * history of pancreatitis

Keywords: anxious major depressive disorder
glucagon responses during oral- and iv glucose in patients with type 1 diabetes

Conditions: Hyperglucagonemia; Hyperglycemia; Diabetes Mellitus

Summary: in order to evaluate the potential role of the gastrointestinal (gi) tract in the postprandial hyperglucagonemia, which characterizes type 1 diabetes mellitus (t1dm) (as well as type 2 diabetes mellitus (t2dm)), we wish to investigate the secretion of glucagon in patients with t1dm without residual beta-cell function during 50-g oral glucose tolerance test (ogtt) and during isoglycemic iv glucose infusion. by evaluating c-peptide negative patients with t1dm we aim to describe the glucagon response to glucose (+/-stimulation of the gi tract) independently of the potentially very important regulation of glucagon secretion by endogenous insulin secretion. a more detailed understanding of the inappropriate glucagon secretion in t1dm is highly needed in order to establish new intervention strategies in the future treatment of the growing numbers of t1dm patients.


Eligibility criteria:
inclusion criteria: * caucasian over 18 years with t1dm (diagnosed according to who's criteria) treated with long-acting insulin * no residual beta-cell function (arginine test without increment in plasma c-peptide - see below) * bmi \<30 kg/m2 * normal haemoglobin * informed consent exclusion criteria: * residual beta-cell function (increment in plasma c-peptide during arginine test - see below) * known liver disease or affected liver enzymes (alat/asat \> 2 x upper normal limit) * diabetic nephropathy (se-creatinin \> 130 µm and/or albuminuria) * proliferative diabetic retinopathy (anamnestic) * treatment with medication that cannot be discontinued for 14 hours